| Source HCPCS Code |
|
Target NDC Code |
J1323
Injection, elranatamab-bcmm, 1 mg
|
⇄
|
00069-2522-01
ELREXFIO 44 MG/1.1 ML VIAL
|
| Detail Information |
| Relationship Start Date |
04/01/2024 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
1.1 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VIAL |
| Route Of Administration |
SQ |
| Billing Units |
ML |
|
|
|
J1323
INJECTION, ELRANATAMAB-BCMM, 1 MG
|
⇄
|
00069-2522-02
ELREXFIO (PF,LATEX-FREE) 40 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
04/01/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
1.1 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
SC |
| Billing Units |
ML |
|
|
|
J1323
Injection, elranatamab-bcmm, 1 mg
|
⇄
|
00069-4494-01
ELREXFIO 76 MG/1.9 ML VIAL
|
| Detail Information |
| Relationship Start Date |
04/01/2024 |
| Relationship End Date |
12/31/3999 |
| Number Of Items In Ndc Package |
1.9 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
VIAL |
| Route Of Administration |
SQ |
| Billing Units |
ML |
|
|
|
J1323
INJECTION, ELRANATAMAB-BCMM, 1 MG
|
⇄
|
00069-4494-02
ELREXFIO (PF,LATEX-FREE) 40 MG/1 ML
|
| Detail Information |
| Relationship Start Date |
04/01/2024 |
| Relationship End Date |
99/99/9999 |
| Number Of Items In Ndc Package |
1.9 |
| Ndc Package Measure |
ML |
| Ndc Package Type |
|
| Route Of Administration |
SC |
| Billing Units |
ML |
|
|
|
J1323
Inj, elranatamab-bcmm, 1 mg
|
⇄
|
00069-2522-02
Elrexfio
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|
J1323
Inj, elranatamab-bcmm, 1 mg
|
⇄
|
00069-4494-02
Elrexfio
|
| Detail Information |
| Relationship Start Date |
|
| Relationship End Date |
|
| Number Of Items In Ndc Package |
|
| Ndc Package Measure |
|
| Ndc Package Type |
|
| Route Of Administration |
|
| Billing Units |
|
|
|
|